https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2014-04-01 / Cancer Immunol Res 2014 Apr;2(4):295-300
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2014-04-01 / Cancer Immunol Res 2014 Apr;2(4):295-3002014-04-01 00:00:002019-02-15 09:22:37Oncolytic viruses and their application to cancer immunotherapy
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2014-03-15 / Virus Res. 2014 Jun;185:10-22
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2014-03-15 / Virus Res. 2014 Jun;185:10-222014-03-15 00:00:002019-02-15 09:21:26Gene expression profiling in PC12 cells infected with an oncolytic Newcastle disease virus strain
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2014-03-12 / Cell Host Microbe 2014 Mar;15(3):260-5
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2014-03-12 / Cell Host Microbe 2014 Mar;15(3):260-52014-03-12 00:00:002019-02-15 09:23:10Viruses for tumor therapy
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2014-03-07 / Immunol. Lett. 2014 May-Jun;159(1-2):36-46
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2014-03-07 / Immunol. Lett. 2014 May-Jun;159(1-2):36-462014-03-07 00:00:002019-02-15 09:21:26Genetically engineered Newcastle disease virus expressing interleukin 2 is a potential drug candidate for cancer immunotherapy
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2014-03-05 / Sci Transl Med 2014 Mar;6(226):226ra32
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2014-03-05 / Sci Transl Med 2014 Mar;6(226):226ra322014-03-05 00:00:002019-02-15 08:36:15Localized oncolytic virotherapy overcomes systemic tumor resistance to immune checkpoint blockade immunotherapy
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2014-01-06 / Oncoimmunology 2014 Jan;3(1):e27622
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2014-01-06 / Oncoimmunology 2014 Jan;3(1):e276222014-01-06 00:00:002019-02-15 09:21:25Two is better than one: Complementing oncolytic virotherapy with gemcitabine to potentiate antitumor immune responses
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2014-01-03 / Cancer Gene Ther. 2014 Jan;21(1):24-30
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2014-01-03 / Cancer Gene Ther. 2014 Jan;21(1):24-302014-01-03 00:00:002014-01-03 00:00:00Different responses of human pancreatic adenocarcinoma cell lines to oncolytic Newcastle disease virus infection
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2013-09-11 / Mol. Cancer 2013 Sep;12(1):103
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2013-09-11 / Mol. Cancer 2013 Sep;12(1):1032013-09-11 00:00:002019-02-15 09:22:36Oncolytic viruses as therapeutic cancer vaccines
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2013-08-19 / Anat Rec (Hoboken) 2013 Oct;296(10):1552-60
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2013-08-19 / Anat Rec (Hoboken) 2013 Oct;296(10):1552-602013-08-19 00:00:002019-02-15 09:21:27TRAIL is involved in the tumoricidal activity of mouse natural killer cells stimulated by Newcastle disease virus in vitro
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2013-07-02 / Biology (Basel) 2013 Jul;2(3):936-75
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2013-07-02 / Biology (Basel) 2013 Jul;2(3):936-752013-07-02 00:00:002021-11-15 16:56:11Oncolytic Newcastle Disease Virus as Cutting Edge between Tumor and Host
